GLP-1 Half-Life / Medication-Level Visualizer

See an educational remaining-fraction curve from the labeled elimination half-life — not a measured blood level.

The curve is first-order remaining fraction: remaining = 0.5^(hours ÷ labeled half-life hours). Results are dose-equivalents of the most recent dose (that dose = 100%), not ng/mL. A generic weekly count does not accumulate. Same-strength leftover requires an explicit confirmation that every counted dose was the same milligram strength. If strength changed, each milligram in the newest-first history is weighted by (that dose ÷ most recent dose) only when the current label states dose-proportional exposure for those strengths. The current Ozempic label makes that claim for 0.5 mg, 1 mg, and 2 mg, not for the 0.25 mg initiation dose; leftover from 0.25 mg is not weighted. Leftover from more than one dose also requires confirmation that those doses occurred on an uninterrupted once-weekly 7-day schedule. Missed, delayed, or early doses fail closed to the single-dose curve; the model does not invent irregular intervals. Wegovy and Ozempic use the labeled “approximately 1 week” half-life as 7 days. Mounjaro uses the labeled “approximately 5 days.” Zepbound uses the labeled 5-to-6-day range as a band, not a single invented midpoint. The model does not draw absorption, body weight, or an unlabeled strength. Dates, if entered, only compute elapsed calendar days since the most recent dose.

• Your actual blood or serum medication level.
• Whether to take a dose early, late, split, or skipped.
• Whether to switch medications, discontinue, or treat an emergency.
• How leftover from a different milligram strength compares unless you enter that labeled history.
• How leftover from missed, delayed, or early doses compares. Use the single-dose curve unless every counted dose was 7 days apart.
• How leftover from an Ozempic 0.25 mg initiation dose compares to a later 0.5 mg, 1 mg, or 2 mg dose. The current label does not state dose-proportional exposure at 0.25 mg.

• WEGOVY (semaglutide) injection / tablet prescribing information

  U.S. National Library of Medicine DailyMed / Novo Nordisk · 2026-06 · Last verified 2026-09-16

  Used for Wegovy injection missed-dose, labeled weekly schedule, presentation-specific storage, and labeled injection pharmacokinetics (approximately 1-week half-life; present about 5 to 7 weeks after the last 2.4 mg or 7.2 mg injection). Tablet rules are not encoded.

• OZEMPIC (semaglutide) injection prescribing information

  U.S. National Library of Medicine DailyMed / Novo Nordisk · Last verified 2026-09-16

  Used for Ozempic missed-dose, labeled weekly schedule, pen/syringe storage, and labeled injection pharmacokinetics (approximately 1-week half-life; present about 5 weeks after the last dose; steady state after 4 to 5 weekly doses).

• OZEMPIC (semaglutide) U.S. Prescribing Information

  Novo Nordisk · Last verified 2026-09-16

• ZEPBOUND (tirzepatide) injection prescribing information

  U.S. National Library of Medicine DailyMed / Eli Lilly · Last verified 2026-09-16

  Used for Zepbound missed-dose, labeled weekly schedule, presentation-specific storage, and labeled injection pharmacokinetics (approximately 5-to-6-day half-life; steady state after 4 weekly doses).

• ZEPBOUND (tirzepatide) U.S. Prescribing Information

  Eli Lilly and Company · Last verified 2026-09-16

• MOUNJARO (tirzepatide) injection prescribing information

  U.S. National Library of Medicine DailyMed / Eli Lilly · Last verified 2026-09-16

  Used for Mounjaro missed-dose, labeled weekly schedule, presentation-specific storage, and labeled injection pharmacokinetics (approximately 5-day half-life; steady state after 4 weekly doses).